Compare SJ & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SJ | GRML |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | United States |
| Employees | N/A | 5 |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 51.5M |
| IPO Year | 2018 | 2022 |
| Metric | SJ | GRML |
|---|---|---|
| Price | $1.14 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 59.7K | ★ 2.9M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.27 |
| 52 Week High | $1.63 | $0.55 |
| Indicator | SJ | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 48.38 | 44.01 |
| Support Level | $1.07 | $0.33 |
| Resistance Level | $1.59 | $0.43 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 41.07 | 13.21 |
Scienjoy Holding Corp is a provider of mobile live streaming platforms in China and focuses on interactive show live streaming from broadcasters to users. It operates a mobile live streaming business by which it provides live streaming entertainment from professional broadcasters to end-users, allowing for the operation of live social video communities. Using its mobile applications, users can select broadcasters and enter real-time video rooms to interact with them. In addition to the real-time interaction, users can also view photos posted by broadcasters in their personal pages, leave comments, and engage in private chats with broadcasters when such broadcasters are not streaming. In addition, users can also play simple, fun games using virtual currencies within the video rooms.
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.